EGFR and non-small cell lung carcinoma: Subgroup analysis of KEYNOTE-024 study (49) revealed that among elderly patients with advanced NSCLC exhibiting high expression of programmed cell death ligand 1 (PD-L1) (TPS ≥50%) and lacking EGFR/ALK mutations, pembrolizumab was consistent with the overall population in extending OS and significantly outperformed chemotherapy (HR=0.64, 95% CI: 0.42-0.98).